Endonovo Therapeutics Inc Share Price OTC Bulletin Board
Equities
US4111551044
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
2023 | Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
2023 | Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval | CI |
Sales 2021 | 0.07 6.11 | Sales 2022 | 0.14 11.32 | Capitalization | 34.98L 29Cr |
---|---|---|---|---|---|
Net income 2021 | -30L -25Cr | Net income 2022 | -1.8Cr -150.52Cr | EV / Sales 2021 | 11,24,21,804 x |
Net Debt 2021 | 70.95L 59Cr | Net Debt 2022 | 71.53L 60Cr | EV / Sales 2022 | 7,86,89,579 x |
P/E ratio 2021 |
-0.3
x | P/E ratio 2022 |
-0.14
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 77.47% |
Managers | Title | Age | Since |
---|---|---|---|
Alan Collier
CEO | Chief Executive Officer | 59 | 01/12/01 |
Steven Barnes
IRC | Investor Relations Contact | - | 01/14/01 |
Corporate Officer/Principal | 68 | 01/22/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Collier
CEO | Chief Executive Officer | 59 | 01/12/01 |
1st Jan change | Capi. | |
---|---|---|
+20.03% | 13TCr | |
+23.61% | 12TCr | |
+22.77% | 2.75TCr | |
-18.07% | 2.09TCr | |
-14.29% | 1.7TCr | |
-14.81% | 1.63TCr | |
+9.78% | 1.46TCr | |
-46.10% | 1.51TCr | |
+52.34% | 1.39TCr |